Identifying the primary tumour in patients with cancer of unknown primary (CUP) using [18F]FDG PET/CT: a systematic review and individual patient data meta-analysis
Authors:
Open Access
- 14 August 2024
- journal article
- review article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (1) , 225-236
Abstract
Purpose: In this systematic review and individual patient data (IPD) meta-analysis, we analysed the diagnostic performance of [18F]FDG PET/CT in detecting primary tumours in patients with CUP and evaluated whether the location of the predominant metastatic site influences the diagnostic performance. Methods: A systematic literature search from January 2005 to February 2024 was performed to identify articles describing the diagnostic performance of [18F]FDG PET/CT for primary tumour detection in CUP. Individual patient data retrieved from original articles or obtained from corresponding authors were grouped by the predominant metastatic site. The diagnostic performance of [18F]FDG PET/CT in detecting the underlying primary tumour was compared between predominant metastatic sites. Results: A total of 1865 patients from 32 studies were included. The largest subgroup included patients with predominant bone metastases (n = 622), followed by liver (n = 369), lymph node (n = 358), brain (n = 316), peritoneal (n = 70), lung (n = 67), and soft tissue (n = 23) metastases, leaving a small group of other/undefined metastases (n = 40). [18F]FDG PET/CT resulted in pooled detection rates to identify the primary tumour of 0.74 (for patients with predominant brain metastases), 0.54 (liver-predominant), 0.49 (bone-predominant), 0.46 (lung-predominant), 0.38 (peritoneal-predominant), 0.37 (lymph node-predominant), and 0.35 (soft-tissue-predominant). Conclusion: This individual patient data meta-analysis suggests that the ability of [18F]FDG PET/CT to identify the primary tumour in CUP depends on the distribution of metastatic sites. This finding emphasises the need for more tailored diagnostic approaches in different patient populations. In addition, alternative diagnostic tools, such as new PET tracers or whole-body (PET/)MRI, should be investigated.Keywords
This publication has 58 references indexed in Scilit:
- Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Performance of 18F-FDG-PET/CT as a next step in the search of occult primary tumors for patients with head and neck squamous cell carcinoma of unknown primary: a systematic review and meta-analysisClinical and Translational Imaging, 2021
- Clinical Impact of F-18 FDG PET-CT on Biopsy Site Selection in Patients with Suspected Bone Metastasis of Unknown Primary SiteNuclear Medicine and Molecular Imaging, 2020
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant DataJAMA, 2015
- The Role of 18 FDG PET-CT in Evaluation of Unknown Primary TumoursIndian Journal of Surgical Oncology, 2013
- Role of diffusion-weighted magnetic resonance imaging in the diagnosis of gallbladder cancerJournal of Magnetic Resonance Imaging, 2012
- Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primaryEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- 18F-FDG PET/CT in the assessment of carcinoma of unknown primary originLa radiologia medica, 2006
- Role of 18F-FDG PET–CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Diagnostic strategies in cervical carcinoma of an unknown primary (CUP)European Archives of Oto-Rhino-Laryngology, 2002